Mid cap News

Palantir Technologies’ shares were down nearly 5% in Friday’s midday trade after an internal army memo reportedly flagged “fundamental security” problems in a U.S. Army communications system that the company is working on.

While Dow Jones futures were up by 0.22% at the time of writing, the S&P 500 futures rose 0.2%.

The stock drew investor attention following commentary from Opendoor CEO Kaz Nejatian and co-founder and board chair Keith Rabois.

The broader market momentum coincided with the stablecoin sector crossing $300 billion in capitalization for the first time, and Bitcoin ETFs recording more than $2 billion in inflows this week.

While Dow Jones futures were down by 0.08% at the time of writing, the S&P 500 futures gained 0.28%.

Bullish’s Oct. 8 crypto options launch, backed by partners such as Galaxy Digital and Flow Traders, aims to expand its institutional trading platform.

Lithium Americas’ shares were up nearly 27% in Wednesday’s midday trade after the U.S. government confirmed that it would pick up a 5% stake in the company.

The St. Petersburg, Florida-based insurer raised $368 million through the IPO, with 18.42 million shares on offer.

The Amarillo, Texas-based data center real estate investment trust raised $682.5 million through the IPO, with 32.5 million shares on offer.

Morgan Stanley noted Upstart’s shift toward super-prime borrowers, who accounted for 26% of originations in Q2 2025, as well as a year-over-year improvement in delinquencies.

Platform data indicate that chatter increased by 48% in the last 24 hours and by more than 200% over the past month.

According to data from Coinglass, the cryptocurrency market saw around $623 million in liquidations over the past 24 hours as major tokens staged a rebound.

While Dow Jones futures were down by 0.49% at the time of writing, the S&P 500 futures fell 0.56%.

The company said that its first next-generation BlueBird 6 satellite has completed final assembly and is set to depart for India on Oct. 12.

Wolfspeed’s shares were up more than 41% during Tuesday’s afternoon session after the company announced that it had exited Chapter 11 bankruptcy.

The company announced that these new offerings on the UiPath Platform for agentic automation are available starting Tuesday.

While Dow Jones futures were down by 0.28% at the time of writing, the S&P 500 futures fell 0.23%.

A shutdown would freeze congressional work, including Senate consideration of the digital asset market structure bill.

Following the restructuring, the company stated that it has reduced its total debt by approximately 70% and extended debt maturities to 2030, while also lowering annual interest expenses by around 60%.

The company plans to integrate the Worldcoin token into its digital asset treasury through a $70 million convertible note private placement.

RBC Capital downgraded the stock, calling the results a “near-miss” statistically and warning that the drug’s effect size looked uncompetitive.

Short interest in Tempus AI climbed to a record 25.7% last week as shares fell 19% from recent highs, even after Guggenheim raised its price target.

The stock pulled back approximately 15% from its peak before closing the week at $21.71.

Merus’ cancer drug petosemtamab, developed for head and neck tumors, has shown stronger results than the current standard of care and is projected to top $1 billion in annual sales by 2030.

MoonLake said it plans to discuss the Phase 3 results with regulators to confirm the path toward approval of sonelokimab for hidradenitis suppurativa, with 52-week data expected in the second quarter of 2026.

The drop comes amid a broader decline in fintech company stocks, including that of Affirm Holdings and Jack Dorsey-backed Block Inc.

The pullback comes ahead of the August release of the Personal Consumption Expenditures price index, due later this Friday.

The company plans to launch in the U.S. in early October, with a European launch expected in 2026.

Transocean increased its planned share offering from 100 million to 125 million shares at $3.05 per share.

More than 500 lawsuits over Tylenol and autism were dismissed last year, but families are now appealing to the 2nd U.S. Circuit Court of Appeals, which is scheduled to hear arguments on Oct. 6.

UniQure said the high-dose of its AMT-130 therapy slowed Huntington’s disease progression by up to 75% over three years and plans to seek FDA approval in early 2026.

KBR announced that, following the spin-off, Stuart Bradie will serve as the new Chair, President, and Chief Executive Officer of KBR.

Freeport said that for the third quarter of 2025, its consolidated sales are expected to be approximately 4% lower for copper and approximately 6% lower for gold than the July 2025 estimates.

Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the firm confirmed that it is in talks with the Energy Department and GM over the $2.6 billion Thacker Pass project loan.

Jefferies raised its price target on the stock to $31, up from $24, and noted that there are "some early signs of over-exuberance" in the stock.

According to a Bloomberg report, the Pentagon in July agreed to a $400 million preferred equity investment in the company.

Glassnode reported U.S. spot bitcoin ETF flows turned mildly negative after strong September inflows, signaling a pause in institutional demand.

While Dow Jones futures were down by 0.02% at the time of writing, the S&P 500 futures rose 0.13%.

South Korea’s drug regulator said it will seek information from companies following U.S. claims about Tylenol and autism.

Quantum technology stocks have seen strength in recent sessions amid reports that President Donald Trump’s administration is considering a broader set of actions related to quantum computing.

Kenvue is facing renewed litigation risks, activist investor pressure, and a challenging consumer backdrop as it undertakes a portfolio review under interim CEO Kirk Perry.

Bernstein noted that the company is becoming less capital-intensive and should trade at a higher multiple.

Archer Aviation announced that its Midnight aircraft completed its highest altitude flight to date, reaching altitudes of 7,000 feet, after taking off from the company’s test facility in Salinas, California.

Citi noted that Kenvue shares would be trading higher on Tuesday following yesterday's selloff, given the lack of new scientific evidence presented by the Trump administration regarding Tylenol use.

According to a Reuters report, the company secured a sole-source contract to supply antimony metal ingots for the defense stockpile.

Bitcoin’s fall to $113,000 pushed futures open interest down to $42.8 billion, which Glassnode called a “healthy reset” that could stabilize derivatives markets and reduce liquidation risk.

While Dow Jones futures were up 0.13% at the time of writing, the S&P 500 futures edged lower by 0.03%.

On Stocktwits, the SoundHound stream saw a 1,844% spike in 24-hour message volume leading up to late Monday.

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

Investors weighed political scrutiny and unproven health claims as Tylenol’s maker faced renewed controversy, sparking volatility in Kenvue’s stock.